why did fda ban tirzepatide BANS Compounded Tirzepatide! Now What? FDA says years-long tirzepatide shortage

Several recent CVOTs have shown that GLP-1RAs can reduce the decline of estimated GFR (eGFR) and delay the onset of the occurrence of proteinuria in patients with T2DM [4, 22, 26, 46, 47]

Monitor periodically

Healthcare providers usually recommend gradual dose escalation to minimize gastrointestinal symptoms

PlexusDx sources all medications from licensed 503A compounding pharmacies and serves all 50 states with no insurance required, making it accessible and affordable from day one

The need for ongoing treatment often surprises people who view obesity as a problem to be solved rather than a chronic condition to be managed

Unlike selective GLP-1 receptor agonists, GLP2s unique dual-action mechanism activates both incretin pathways simultaneously, representing a novel therapeutic class often referred to as twincretins. The peptides strategic design includes lipidation with a C20 fatty diacid moiety attached via a hydrophilic linker, which enables albumin binding and extends its half-life to approximately 5 days, permitting convenient once-weekly dosing